A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2017
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma; Novartis Pharmaceuticals
- 01 Jun 2016 The trial was prematurely ended in Italy (end date: 2016-01-25).
- 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.